首页> Current medical research and opinion> Everolimus use and associated factors among post-menopausal women with hormonal receptor positive/human epidermal growth factor receptor 2 negative metastatic breast cancer

Everolimus use and associated factors among post-menopausal women with hormonal receptor positive/human epidermal growth factor receptor 2 negative metastatic breast cancer

导出原文传递

翻译打印收藏纠错

第一作者： Li, Nanxin

作者： Li, Nanxin ^[1] ; Hao, Yanni ^[2] ; Xie, Jipan ^[3] ; Lin, Peggy L. ; Zhou, Zhou ; Zhong, Yichen ; Signorovitch, James E. ; Wu, Eric Q.

作者单位： Anal Grp Inc, Boston, MA 02199 USA ^[1] Novarijs Pharmaceut Corp, E Hanover, NJ USA ^[2] Anal Grp Inc, New York, NY USA ^[3]

关键词 Chemotherapy Endocrine therapy Everolimus HR+/HER2-metastatic breast cancer Treatment patterns

发布时间 2015-11-13

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Current medical research and opinion

2015年31卷8期

1573-1582页

相似文献

中文期刊
外文期刊
学位论文
会议论文

浏览0

Current medical research and opinion

2015年31卷8期

1573-1582页

检索历史清除

Everolimus use and associated factors among post-menopausal women with hormonal receptor positive/human epidermal growth factor receptor 2 negative metastatic breast cancer

Current medical research and opinion

相似文献

同项目论文

Current medical research and opinion

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Everolimus use and associated factors among post-menopausal women with hormonal receptor positive/human epidermal growth factor receptor 2 negative metastatic breast cancer

Current medical research and opinion

相似文献

同项目论文

Current medical research and opinion

相关期刊

检索历史清除